Kayexalate (Sodium Polystyrene Sulfonate)

Kayexalate is a potassium‑binding resin used in the management of disorders that cause elevated serum potassium.

• Hyperkalemia: lowers serum potassium concentrations in acute or chronic settings.
• Acute hyperkalemia: provides rapid removal of excess potassium to prevent cardiac complications.
• Chronic hyperkalemia: helps maintain potassium balance in patients with renal impairment or on potassium‑raising therapies.

• Sodium polystyrene sulfonate acts as a cation exchange resin that exchanges its sodium ions for potassium ions within the gastrointestinal lumen. The bound potassium is then eliminated in the feces, resulting in a net reduction of serum potassium levels without systemic absorption of the resin itself.

Kayexalate may cause a range of adverse reactions, most of which are related to the gastrointestinal tract.

Common Side Effects

• Nausea: mild to moderate discomfort after ingestion.
• Vomiting: occasional expulsion of stomach contents.
• Constipation: reduced bowel movements, may require monitoring.
• Diarrhea: loose stools, often transient.
• Abdominal discomfort: cramping or pain in the abdomen.
• Taste alteration: metallic or unpleasant taste.

Serious or Rare Side Effects

• Intestinal necrosis: rare but severe tissue death, especially with sorbitol.
• Severe electrolyte imbalance: hypokalemia or hypernatremia requiring urgent care.
• Colonic ulceration: ulcer formation in the colon.
• Bowel obstruction: blockage due to severe constipation.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Metabolic acidosis: rare disturbance of acid‑base balance.

Before initiating Kayexalate, clinicians should consider several safety measures.

• Monitor serum potassium: check levels before and during therapy.
• Assess renal function: adjust use in patients with impaired kidney function.
• Evaluate gastrointestinal status: avoid in patients with bowel obstruction or inflammatory bowel disease.
• Use caution with ACE inhibitors or potassium‑sparing diuretics: risk of additive hyperkalemia.
• Avoid concomitant sorbitol‑containing laxatives: increased risk of intestinal necrosis.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Kayexalate can interact with other medicines that affect potassium balance or gastrointestinal integrity.

Major Interactions (Avoid)

• Sorbitol‑containing laxatives: may precipitate intestinal necrosis.
• ACE inhibitors: can exacerbate hyperkalemia.
• Potassium‑sparing diuretics: additive effect on potassium levels.

Moderate Interactions (Monitor Closely)

• Digoxin: potassium shifts may alter digoxin toxicity.
• Lithium: changes in electrolyte balance can affect lithium levels.